Organon Completes Spin-Out From Merck With Five Biosimilars
Adalimumab Recently Launched In Australia And Canada
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
You may also be interested in...
Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.
Samsung Bioepis has received approval from Health Canada for its Ontruzant trastuzumab biosimilar rival to Herceptin in 150mg single-use and 440mg multi-dose vials. The product will be marketed in Canada by Organon.